143 related articles for article (PubMed ID: 18609744)
1. Drug use and toxicity in psoriatic disease: focus on methotrexate.
Taylor WJ; Korendowych E; Nash P; Helliwell PS; Choy E; Krueger GG; Soriano ER; McHugh NJ; Rosen CF
J Rheumatol; 2008 Jul; 35(7):1454-7. PubMed ID: 18609744
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary focus on methotrexate in psoriatic disesase.
Marchesoni A; Ricci M; Moggio E; Brazzelli V; Borroni G
J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.
Carneiro SC; Cássia FF; Lamy F; Chagas VL; Ramos-e-Silva M
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969
[TBL] [Abstract][Full Text] [Related]
5. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous ulceration as a sign of methotrexate toxicity.
Del Pozo J; Martínez W; García-Silva J; Almagro M; Peña-Penabad C; Fonseca E
Eur J Dermatol; 2001; 11(5):450-2. PubMed ID: 11525955
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?
Lindsay K; Gough A
Rheumatology (Oxford); 2008 Jul; 47(7):939-41. PubMed ID: 18474510
[No Abstract] [Full Text] [Related]
8. Accelerated nodulosis in a patient with psoriasis and arthritis during treatment with methotrexate.
Berris B; Houpt JB; Tenenbaum J
J Rheumatol; 1995 Dec; 22(12):2359-60. PubMed ID: 8835577
[TBL] [Abstract][Full Text] [Related]
9. A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.
Mathew J; Leong MY; Morley N; Burt AD
BMC Dermatol; 2005 Nov; 5():12. PubMed ID: 16316460
[TBL] [Abstract][Full Text] [Related]
10. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Boffa MJ; Smith A; Chalmers RJ
Rheumatology (Oxford); 2009 Nov; 48(11):1464; author reply 1465. PubMed ID: 19671697
[No Abstract] [Full Text] [Related]
11. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients.
Wollina U; Ständer K; Barta U
Clin Rheumatol; 2001; 20(6):406-10. PubMed ID: 11771523
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
Malatjalian DA; Ross JB; Williams CN; Colwell SJ; Eastwood BJ
Can J Gastroenterol; 1996 Oct; 10(6):369-75. PubMed ID: 9193771
[TBL] [Abstract][Full Text] [Related]
13. [Methotrexate: safe if prescribed correctly].
Verduijn MM; van den Bemt BJ; Dijkmans BA; van der Waal RI; Horikx A
Ned Tijdschr Geneeskd; 2009; 153():A695. PubMed ID: 19785857
[TBL] [Abstract][Full Text] [Related]
14. Visual field changes in methotrexate therapy. Case report and review of the literature.
Sbeity ZH; Baydoun L; Schmidt S; Loeffler KU
J Med Liban; 2006; 54(3):164-7. PubMed ID: 17190135
[TBL] [Abstract][Full Text] [Related]
15. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
16. Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Mease PJ; Gladman DD
J Rheumatol; 2011 Mar; 38(3):522-5. PubMed ID: 21362779
[TBL] [Abstract][Full Text] [Related]
17. Focal skin toxicity related to methotrexate sparing psoriatic plaques.
Truchuelo T; Alcántara J; Moreno C; Vano-Galván S; Jaén P
Dermatol Online J; 2010 Jun; 16(6):16. PubMed ID: 20579471
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate use in psoriasis and psoriatic arthritis.
Cuellar ML; Espinoza LR
Rheum Dis Clin North Am; 1997 Nov; 23(4):797-809. PubMed ID: 9361156
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate hepatotoxicity: what is the evidence?
Ahern MJ; Smith MD; Roberts-Thomson PJ
Inflamm Res; 1998 Apr; 47(4):148-51. PubMed ID: 9628257
[No Abstract] [Full Text] [Related]
20. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.
Rademaker M; Gupta M; Andrews M; Armour K; Baker C; Foley P; Gebauer K; George J; Rubel D; Sullivan J
Australas J Dermatol; 2017 Aug; 58(3):166-170. PubMed ID: 27402434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
